Join
Live feed
·
FDARegulatoryvia Quantisnow
Regeneron Pharmaceuticals Inc. logo

May 20, 2022 - FDA Approves First Treatment for Eosinophilic Esophagitis, a Chronic Immune Disorder

ByQuantisnow·Wall Street's wire, on your screen.
REGN· Regeneron Pharmaceuticals Inc.
Health Care
Original source

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track REGN (Regeneron Pharmaceuticals Inc.) and more on Quantisnow.